Compare Manulife Financial Corporation (MFC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Manulife Financial Corporation trades at $42.43 (market cap $69.48B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Manulife Financial Corporation is far larger — about 6.9× State Street SPDR S&P Biotech ETF's market cap, and Manulife Financial Corporation pays a 3.23% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MFC | XBI | |
|---|---|---|
Market Cap | $69.48B | $10.11B |
Volume | 1,347,508 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $44.77 | $169.55 |
52-Week Low | $31.64 | $104.99 |
Typical Hold Time | 119 Days | 38 Days |
Enterprise Value | $64.75B | — |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $42.12, up 1.08% today, with a bearish technical signal from moving averages. Revenue grew to $53.01B in 2025, with a net income margin of 11.7%, while Q2 2026 earnings beat expectations. Analyst consensus is bullish with 57% buy ratings, though the consensus price target of $34.24 is below the current price. Recent news includes a new $750M subordinated notes offering and executive appointments.
Outlook is mixed: strong fundamentals and institutional interest support upside, but technical weakness and a high valuation relative to the price target pose risks. Key catalysts include Q3 2026 earnings and execution of growth initiatives in Asia.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
